MDTC yields 3816.79% · ABBV yields 3.06%● Live data
📍 MDTC pulled ahead of the other in Year 1
Combined, MDTC + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MDTC + ABBV for your $10,000?
Media Technologies, Inc., a full service paper converting company, manufactures and sells custom folding cartons primarily in the United States. The company provides die-cut header cards, clam shell inserts, chipboard slip sheets, and chipboard boxes. It offers solid bleached sulfate for use in cosmetic and pharmaceutical, ice cream, bakery and other food, and additional high-end packaging applications; gypsum used to convert brick divider sheets; and folding cartons for various retail packaging requirements, including cosmetics, candies, dog treats, frozen food and hardware products, pharmaceuticals, and textiles. The company also provides engineering plotter rolls; clay coated news back CCNB for various uses, such as color-printed folding cartons; and chipboards for various packaging and art applications, as well as wide format ink jet media and custom folders. In addition, it converts a range of premium paper stocks and packaging solutions. The company was formerly known as Town and Country Appraisal Service, Inc. and changed its name to Media Technologies, Inc. in June 2010. Media Technologies, Inc. was founded in 1976 and is based in Oklahoma City, Oklahoma.
Full MDTC Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.